Balthaser Kevin 4

What Happened
Kevin Balthaser, Chief Financial Officer of Aclaris Therapeutics (ACRS), was granted two restricted stock unit (RSU) awards on February 2, 2026, totaling 445,900 RSUs (99,100 and 346,800). The grants are reported as derivative awards at $0.00 per share (i.e., contingent rights to receive common stock upon vesting), not open-market purchases or sales.

Key Details

• Transaction date: 2026-02-02; Report filed: 2026-02-06 (filing timeliness not specified in the provided data).
• Grants: 99,100 RSUs and 346,800 RSUs, reported at $0.00 (derivative awards). Total = 445,900 RSUs.
• Shares owned after transaction: Not disclosed in the provided filing summary.
• Footnotes: F1 — each RSU represents a contingent right to one share; F2 — RSUs vest in four equal annual installments on the 1st, 2nd, 3rd and 4th anniversaries of Feb 2, 2026, subject to continuous service; F3 — describes a 25%/four‑installment vesting schedule applicable to option-related awards referenced in the filing.
• No sale or exercise reported — these are award grants (code A).

Context
RSUs are not immediate stock ownership: they convert to shares only as they vest and subject to the executive remaining in service per the plan. This filing shows compensation-related equity grants rather than insider buying or selling; such grants are common for executive pay and retention and do not by themselves indicate open-market buying interest.